Last reviewed · How we verify

RAGWEED 12 AMB A 1-U

Clinique Spécialisée en Allergies de la Capitale · FDA-approved active Small molecule

RAGWEED 12 AMB A 1-U is a Allergen extract immunotherapy Small molecule drug developed by Clinique Spécialisée en Allergies de la Capitale. It is currently FDA-approved for Ragweed pollen allergy (allergic rhinitis and/or allergic asthma), Immunotherapy desensitization to ragweed allergens. Also known as: RAGWITEK.

Ragweed pollen extract allergen immunotherapy that desensitizes the immune system to ragweed allergens through repeated controlled exposure.

Ragweed pollen extract allergen immunotherapy that desensitizes the immune system to ragweed allergens through repeated controlled exposure. Used for Ragweed pollen allergy (allergic rhinitis and/or allergic asthma), Immunotherapy desensitization to ragweed allergens.

At a glance

Generic nameRAGWEED 12 AMB A 1-U
Also known asRAGWITEK
SponsorClinique Spécialisée en Allergies de la Capitale
Drug classAllergen extract immunotherapy
TargetRagweed pollen allergens (Amb a 1 and related epitopes)
ModalitySmall molecule
Therapeutic areaImmunology / Allergy
PhaseFDA-approved

Mechanism of action

This is an allergen extract preparation containing ragweed (Ambrosia) pollen antigens used in immunotherapy. It works by gradually inducing immune tolerance to ragweed allergens, reducing allergic responses upon natural exposure. The standardized potency (1-U) allows for controlled dosing in allergy treatment protocols.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about RAGWEED 12 AMB A 1-U

What is RAGWEED 12 AMB A 1-U?

RAGWEED 12 AMB A 1-U is a Allergen extract immunotherapy drug developed by Clinique Spécialisée en Allergies de la Capitale, indicated for Ragweed pollen allergy (allergic rhinitis and/or allergic asthma), Immunotherapy desensitization to ragweed allergens.

How does RAGWEED 12 AMB A 1-U work?

Ragweed pollen extract allergen immunotherapy that desensitizes the immune system to ragweed allergens through repeated controlled exposure.

What is RAGWEED 12 AMB A 1-U used for?

RAGWEED 12 AMB A 1-U is indicated for Ragweed pollen allergy (allergic rhinitis and/or allergic asthma), Immunotherapy desensitization to ragweed allergens.

Who makes RAGWEED 12 AMB A 1-U?

RAGWEED 12 AMB A 1-U is developed and marketed by Clinique Spécialisée en Allergies de la Capitale (see full Clinique Spécialisée en Allergies de la Capitale pipeline at /company/clinique-sp-cialis-e-en-allergies-de-la-capitale).

Is RAGWEED 12 AMB A 1-U also known as anything else?

RAGWEED 12 AMB A 1-U is also known as RAGWITEK.

What drug class is RAGWEED 12 AMB A 1-U in?

RAGWEED 12 AMB A 1-U belongs to the Allergen extract immunotherapy class. See all Allergen extract immunotherapy drugs at /class/allergen-extract-immunotherapy.

What development phase is RAGWEED 12 AMB A 1-U in?

RAGWEED 12 AMB A 1-U is FDA-approved (marketed).

What are the side effects of RAGWEED 12 AMB A 1-U?

Common side effects of RAGWEED 12 AMB A 1-U include Local injection site reactions (erythema, swelling, pruritus), Systemic allergic reactions, Anaphylaxis (rare).

What does RAGWEED 12 AMB A 1-U target?

RAGWEED 12 AMB A 1-U targets Ragweed pollen allergens (Amb a 1 and related epitopes) and is a Allergen extract immunotherapy.

Related